未找到相关数据
Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
被引：8
作者：
Xu, Jian-Ming
Qin, Shukui
Zhang, Yun
Zhang, Yaoyue
Jia, Ru
Liu, Rongrui
Zhang, Gairong
Zhao, Chuanhua
Lu, Ni
Liu, Huilong
Xu, Wenlian
Fu, Meng
Cao, Walt
Lu, Haolan
Liu, David
Dong, Ruiping
Wang, Xiaoxiao
Wang, Pilin
Xu, Ting
Gong, John
机构：
[1] 307 Hosp PLA, Beijing, Peoples R China
[2] Nanjing Univ Chinese Med, Bayi Hosp Affiliated, PLA Canc Ctr, Nanjing, Jiangsu, Peoples R China
[3] 3D Medicines Co Ltd, Sichuan, Sichuan, Peoples R China
[4] Alphamab Co Ltd, Suzhou, Peoples R China
[5] 3D Medicines Co Ltd, Beijing, Peoples R China
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2608
引用
收藏
页数：1
相关论文